within Pharmacolibrary.Drugs.ATC.N;

model N06AX19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 0.0006,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Gepirone is an azapirone class anxiolytic and antidepressant drug structurally related to buspirone. It acts primarily as a serotonin 5-HT1A receptor partial agonist and has been investigated for use in the treatment of anxiety disorders and major depressive disorder. Gepirone is not currently approved for clinical use in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, with oral administration in fasting state.</p><h4>References</h4><ol><li><p>Phillips, B, et al., &amp; St Onge, E (2024). Gepirone: A New Extended-Release Oral Selective Serotonin Receptor Agonist for Major Depressive Disorder. <i>The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians</i> 40(5) 230–235. DOI:<a href=&quot;https://doi.org/10.1177/87551225241269179&quot;>10.1177/87551225241269179</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39493804/&quot;>https://pubmed.ncbi.nlm.nih.gov/39493804</a></p></li><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993656/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li><li><p>Tay, LK, et al., &amp; Pittman, KA (1993). Effect of food on the bioavailability of gepirone in humans. <i>Journal of clinical pharmacology</i> 33(7) 631–635. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1993.tb04715.x&quot;>10.1002/j.1552-4604.1993.tb04715.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8103528/&quot;>https://pubmed.ncbi.nlm.nih.gov/8103528</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX19;
